This site uses cookies to collect activity data and personalize content. By continuing to navigate this site, you agree to allow us to collect information using cookies. Learn more about how we care for your data in our privacy notice.

Pandemic response
COVID-19 is impacting communities around the world. PATH and our partners are responding.

Semisynthetic Artemisinin: Cross-Sector Partnership to Stabilize the Antimalarial Drug Supply

Artemisinin-based combination therapy is considered the gold standard treatment for malaria, but global demand has often outpaced production, and pricing has been volatile. With funding from the Bill & Melinda Gates Foundation, PATH and our partners set out to develop a new pharmaceutical manufacturing process to produce commercial volumes of high-quality, nonseasonal, and affordable artemisinin to supplement the plant-based supply. This poster, presented at the Bay Area World Malaria Day Symposium on April 25, 2014, presents key facts on malaria, the market for artemisinin, partner roles, and commercial production.

Publication date: April 2014

Available materials

    1. Semisynthetic Artemisinin (full size) 790.5 KB PDF

      Hard copies are not available.

    2. Semisynthetic Artemisinin (sized for 8.5 x 11) 628.1 KB PDF